Previous studies have reported that Nampt mRNA is decreased in the liver of human subjects with non-alcoholic fatty liver disease, and Nampt has been shown to protect hepatocytes by increasing SIRT1 activity [36,37]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.